View text source at Wikipedia
Clinical data | |
---|---|
Trade names | Tenelia |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C22H30N6OS |
Molar mass | 426.58 g·mol−1 |
3D model (JSmol) | |
| |
|
Teneligliptin (INN; trade name Tenelia) is a pharmaceutical drug for the treatment of type 2 diabetes mellitus. It belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 inhibitors or "gliptins".[1]
It was created by Mitsubishi Tanabe Pharma and launched in September 2012 by both Mitsubishi Tanabe Pharma and Daiichi Sankyo in Japan.[2]
It is approved for use in Japan, Argentina, Korea and India.[3]
Teneligliptin has unique J-shaped or anchor locked domain structure because of which it has a potent inhibition of DPP 4 enzyme.
Teneligliptin significantly controls glycemic parameters with safety. No dose adjustment is required in renally impaired patients.[4]